| arznei-telegramm® 07/2017 |
SPOT ON |
| Profiteering with orphan drugs … 450-fold price increase within seven years |
NEW ON THE MARKET |
| Baricitinib (OLUMIANT) and tofacitinib (XELJANZ) against rheumatoid arthritis |
THERAPY FROM A CRITICAL VIEWPOINT |
| CANVAS trial with canagliflozin (INVOCANA) – second endpoint trial with an SGLT-2 inhibitor |
| Bioresorbable coronary stents: disappointing results |
a-t READERS QUESTIONS AND COMMENTS |
| Glatiramer acetate generic CLIFT |
IN BRIEF |
| SCORE 2 trial: bevacizumab (AVASTIN) versus aflibercept (EYLEA) in retinal vein occlusion |
| No benefit of high dose baclofen (LIORESAL, generics) in alcohol-dependent patients |
| Azithromycin gel against borreliosis? |
CURRENT ADR NETWORK REPORT |
| Genital mycosis with empagliflozin (JARDIANCE) |
SIDE EFFECTS | Fatal liver failure with daclizumab (ZINBRYTA) |
| Cardiovascular side effects with brimonidine (MIRVASO) |
e a-t ON THE INTERNET |
| Osteonecrosis of the external auditory canal with denosumab (PROLIA, XGEVA) |